Last reviewed · How we verify
Tolvaptan IR — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tolvaptan IR (Tolvaptan IR) — Otsuka Pharmaceutical Development & Commercialization, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tolvaptan IR TARGET | Tolvaptan IR | Otsuka Pharmaceutical Development & Commercialization, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tolvaptan IR CI watch — RSS
- Tolvaptan IR CI watch — Atom
- Tolvaptan IR CI watch — JSON
- Tolvaptan IR alone — RSS
Cite this brief
Drug Landscape (2026). Tolvaptan IR — Competitive Intelligence Brief. https://druglandscape.com/ci/tolvaptan-ir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing